TheraRadar
Landscape / Oncology
Data updated: Jun 28, 2026

Neuroendocrine Tumors Clinical Trial Landscape

Neuroendocrine Tumors is being studied across 326 clinical trials registered since 2008, with 131 programs currently active. The competitive pipeline includes 21 active Phase 3 trials, 80 active Phase 2 trials, and 25 active Phase 1 trials.

Top industry sponsors include Advanced Accelerator Applications, Crinetics Pharmaceuticals Inc., Merck.

Trial activity

131 active / 326 total since 2008
Active by phase 21 Ph3 / 42 80 Ph2 / 204 25 Ph1 / 66 5 Ph4 / 14

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Advanced Accelerator Applications 2 2 0
Crinetics Pharmaceuticals Inc. 2 1 0
Merck 2 0 0
Exelixis 2 0 0
RayzeBio, Inc. 2 0 0
ITM Solucin GmbH 2 0 0
Novartis 1 11 1
Jiangsu HengRui Medicine Co., Ltd. 1 1 1
Roche 1 1 1
Orano Med LLC 1 0 1
Camurus AB 1 1 0
Perspective Therapeutics 1 0 0
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 1 0 0
Teclison Ltd. 1 0 0
Chimeric Therapeutics 1 0 0

All 15 active Neuroendocrine Tumors sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2017 (33 registered); 2025 saw 24. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (31 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
17
2017
33
2018
15
2019
14
2020
16
2021
32
2022
24
2023
16
2024
24
2025
24
2026
7

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (2)
15
2017 (3)
324
2018 (3)
63
2019 (2)
104
2020 (3)
226
2021 (4)
296
2022 (3)
300
2023 (2)
195
2024 (2)
54
2025 (5)
240
2026 (2)
2,650

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT05918302 RECRUITING
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Grupo Espanol de Tumores Neuroendocrinos n=170
NCT03375320 ACTIVE NOT RECRUITING
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI) n=298
NCT07087054 RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. n=141
NCT06784752 RECRUITING
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Novartis Pharmaceuticals n=240
NCT07165886 RECRUITING
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=298
NCT05884255 RECRUITING
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd. n=220
NCT06943755 RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Exelixis n=440
NCT03049189 ACTIVE NOT RECRUITING
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
ITM Solucin GmbH n=324
NCT05477576 RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio, Inc. n=338
NCT04706910 RECRUITING
18F-DOPA II - PET Imaging Optimization
University of Alberta n=800
NCT03972488 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Advanced Accelerator Applications n=226
NCT05050942 ACTIVE NOT RECRUITING
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB n=332
NCT07185672 RECRUITING
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Tata Memorial Hospital n=162
NCT05387603 RECRUITING
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Lund University Hospital n=300
NCT04919226 ACTIVE NOT RECRUITING
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
ITM Solucin GmbH n=259
NCT05459844 ACTIVE NOT RECRUITING
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Sinotau Pharmaceutical Group n=196
NCT06878664 RECRUITING
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Grupo Espanol de Tumores Neuroendocrinos n=166
NCT06855095 RECRUITING
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
The Netherlands Cancer Institute n=39
NCT04847505 RECRUITING
68Ga-DOTA-TATE PET/CT Imaging in NETs
Centre de recherche du Centre hospitalier universitaire de Sherbrooke n=5,000
NCT07591493 NOT YET RECRUITING
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
Gustave Roussy, Cancer Campus, Grand Paris n=300
NCT07620574 NOT YET RECRUITING
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis n=5,000
NCT01744249 COMPLETED
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos n=256
NCT06091748 COMPLETED
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Jiangsu HengRui Medicine Co., Ltd. n=69
NCT02840149 COMPLETED
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Jewish General Hospital n=45
NCT02246127 COMPLETED
Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos n=141
NCT04852679 COMPLETED
Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Ipsen n=43
NCT03136328 COMPLETED
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center n=11
NCT02588170 COMPLETED
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchison Medipharma Limited n=219
NCT02589821 COMPLETED
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchison Medipharma Limited n=195
NCT03673943 COMPLETED
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc. n=63
NCT01842165 COMPLETED
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Jules Bordet Institute n=37
NCT03590119 COMPLETED
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Marnix Lam n=26
NCT02608203 COMPLETED
[68 Ga]-DOTANOC PET/CT in GEP-NETs
Assistance Publique Hopitaux De Marseille n=18
NCT02683941 TERMINATED
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
Ipsen n=77
NCT01578239 COMPLETED
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Advanced Accelerator Applications n=231
NCT04552847 COMPLETED
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven n=85
NCT03042416 COMPLETED
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
University of Alberta n=400
NCT01524783 COMPLETED
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
Novartis Pharmaceuticals n=302
NCT04065165 WITHDRAWN
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
European Organisation for Research and Treatment of Cancer - EORTC
NCT02465112 TERMINATED
Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
GERCOR - Multidisciplinary Oncology Cooperative Group n=4
NCT01755182 TERMINATED
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
National Cancer Institute, Naples n=1
NCT01860742 WITHDRAWN
Randomized Phase III of PRRT Versus Interferon
Jules Bordet Institute

Full Neuroendocrine Tumors Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only